论文部分内容阅读
默沙东实验室新兴市场高级副总裁接受本刊专访,认为中国新药研发最大短板在于缺乏强大的团队覆盖前端研发和后端开发“偌大的中国,到目前为止,还很难说有一个真正意义上进军国际市场的原创新药。”四年前,著名新药专家刘日延博士的一句话,让中国人清醒地认识到我国在创新新药研发方面与国际水平的巨大差距。四年时间过去了,我国在原创新药的研发上仍是长路漫漫。虽然近年来,国内医药行业的投资环境已得到明显改善,国家对科研机构、研发型医药企业的经费支持力度也大幅度提升,但在新药研发过程中,最重要的一环——人才,国内的高端研发人才团队仍没有跟
The senior vice president of Emerging Markets at Merck Building Laboratory, in an exclusive interview, believes that the biggest shortcoming of China’s drug development lies in the lack of a strong team that covers front-end research and development and back-end development. "To date, it is hard to say that there is a real sense Four years ago, Dr. Liu Ranyan, a well-known new drug expert, made the Chinese people soberly aware of the huge gap between China and other countries in research and development of innovative drugs with the international standard. Four years have passed, and our country still has a long way to go in the research and development of original new drugs. Although the investment environment in the domestic pharmaceutical industry has been significantly improved in recent years, the financial support provided by the state to research institutes and research and development-oriented pharmaceutical enterprises has also been greatly enhanced. However, the most important part in the research and development of new drugs - talent, domestic The high-end R & D talent team still does not follow